Premia Spine, Ltd.
$455.3K 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Intrinsic Therapeutics
Intrinsic Therapeutics reported $454,474.63 across General Payments, Research, and Ownership to 1,129 physicians and teaching hospitals across 1,504 transactions.
- $454.5K Above-median payer
- All-tracks total
- 1,504 Top quartile volume
- Transactions
- 1,129 Above-median reach
- Recipients
- +$146.6K
- General Payments vs PY2023
Intrinsic Therapeutics reported $454,474.63 across all CMS Open Payments tracks (General + Research + Ownership) to 1,129 physicians and teaching hospitals in Program Year 2024 - ranking #785 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $300,724.63, averaging $402.55 per recipient.
How Intrinsic Therapeutics's $454.5K all-tracks total breaks down
Intrinsic Therapeutics's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
26/100
Total payments
F
14/100
Transaction volume
F
21/100
Physician reach
F
19/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer intrinsic-therapeutics Intrinsic Therapeutics
$454.5K · #785/1,925 · 0.0% industry · PY2024
- TOT $454.5K
- RANK #785
- SHARE 0.0%
- TXN 1,504
- RCP 1,129
- CAT 4
- GEN $300.7K
- ΔGEN +$146.6K
- TOP1 9.8%
- PY 2024
Volume peers
Nearest volume peer: Premia Spine, Ltd. ($455.3K)
Intrinsic Therapeutics sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Intrinsic Therapeutics's CMS-reported General Payments increased by $146.6K (+95.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: INTRINSIC THERAPEUTICSPY2023: INTRINSIC THERAPEUTICSPY2024: Intrinsic Therapeutics. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $154,126.18
- PY2024
- $300,724.63
What the Data Shows for Intrinsic Therapeutics
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Intrinsic Therapeutics, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 4-category general-payment breakdown below at $140.3K (46.7% of General Payments, 208 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 4 types of general payments, Intrinsic Therapeutics's largest category was "Consulting Fee" at $140.3K - 46.7% of General Payments.
Intrinsic Therapeutics reports 4 general-payment categories - the top three are Consulting Fee (46.7%), Food and Beverage (27.6%), and Compensation for Faculty or Speaker (Medical Education) (13.9%). The remaining 1 category make up 11.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Intrinsic Therapeutics divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $140.3K | 208 | 46.7% |
| Food and Beverage | $83.1K | 817 | 27.6% |
| Compensation for Faculty or Speaker (Medical Education) | $42.0K | 27 | 13.9% |
| Travel and Lodging | $35.3K | 77 | 11.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $119,809.04 (39.8%) of $300,724.63 in this company's General Payments records across 254 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Intrinsic Therapeutics
The five named recipients with the highest reported General Payments from this company
- 1
Keneth Strenge
$29,534.69 across 32 reported transactions
- 2
Sarah Martineck
$28,685.00 across 3 reported transactions
- 3
Adam Lipson
$21,775.62 across 33 reported transactions
- 4
Jason Zook
$20,678.41 across 18 reported transactions
- 5
Betsy Grunch
$19,135.32 across 51 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Intrinsic Therapeutics ranks #785 of 1,925 by total payments (top 41% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,340 of 1,838 by HHI (bottom 27% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Pinnacle Biologics, Inc : $70.6K total payments, HHI 445
- Gentleman Orthopedic Solutions : $20.0K total payments, HHI 445
- Blue Earth Diagnostics Limited : $324.1K total payments, HHI 444
- Trilliant Surgical LLC. : $844.6K total payments, HHI 443
- Innovasis Inc : $1.1M total payments, HHI 441
- Avadel CNS Pharmaceuticals, LLC : $1.5M total payments, HHI 441
- Intrinsic Therapeutics (this company) : $300.7K total payments, HHI 441
- Braeburn Inc. : $1.2M total payments, HHI 439
- Arthrex, Inc. : $104.3M total payments, HHI 439
- Uoc USA Inc : $460.8K total payments, HHI 437
- ZOLL Respicardia, Inc. : $325.9K total payments, HHI 435
- Vasorum USA Inc. : $12.3K total payments, HHI 435
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Intrinsic Therapeutics's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Intrinsic Therapeutics.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Intrinsic Therapeutics.
Showing 6 of 1,924 companies with CMS-reported payment data.
Gamida Cell Inc.
$452.0K 9 recipients
Compare payment profiles
Molnlycke Health Care Ab
$449.3K 0 recipients
Compare payment profiles
Uoc USA Inc
$460.8K 347 recipients
Compare payment profiles
Nuwellis, Inc.
$447.8K 251 recipients
Compare payment profiles
Virtual Incision Corporation
$447.4K 683 recipients
Compare payment profiles
Put this to use
Intrinsic Therapeutics ranks #785 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Intrinsic Therapeutics. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.